Abstract
Atenolol reduces QT dispersion and corrected QT interval in patients with syndrome X. This suggests that symptomatic improvement induced by atenolol in syndrome X patients may be partly related to reduction in abnormally augmented sympathetic tone.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use*
-
Atenolol / therapeutic use*
-
Electrocardiography / drug effects*
-
Female
-
Humans
-
Male
-
Microvascular Angina / drug therapy*
-
Middle Aged
Substances
-
Adrenergic beta-Antagonists
-
Atenolol